Hyperglycemia - Pipeline Review, H1 2017

  • ID: 4318724
  • Report
  • 30 pages
  • Global Markets Direct
1 of 5
Hyperglycemia - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia - Pipeline Review, H1 2017, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Hyperglycemia - Overview
  3. Hyperglycemia - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Hyperglycemia - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Hyperglycemia - Companies Involved in Therapeutics Development
  15. Mitsubishi Tanabe Pharma Corp
  16. Hyperglycemia - Drug Profiles
  17. Drugs to Inhibit ABHD6 for Metabolic Disorders - Drug Profile
  18. Product Description
  19. Mechanism Of Action
  20. R&D Progress
  21. FGH-10019 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. KR-62980 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. Hyperglycemia - Dormant Projects
  50. Hyperglycemia - Discontinued Products
  51. Appendix
  52. Methodology
  53. Coverage
  54. Secondary Research
  55. Primary Research
  56. Expert Panel Validation
  57. Contact Us
  58. Disclaimer
List of Tables
  1. Number of Products under Development for Hyperglycemia, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corp, H1
  11. Hyperglycemia - Dormant Projects, H1
  12. Hyperglycemia - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Hyperglycemia, H1
  2. Number of Products under Development by Universities/Institutes, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Mitsubishi Tanabe Pharma Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll